Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Novantrone
Mitoxantrone is an antineoplastic agent, specifically a type II topoisomerase inhibitor, used in the treatment of certain cancers. It interferes with DNA synthesis and repair, ultimately leading to cell death. Mitoxantrone is indicated for the treatment of acute myeloid leukemia, prostate cancer, and multiple sclerosis.
Used to treat certain types of cancer, such as acute myeloid leukemia and prostate cancer, and to manage multiple sclerosis.
Mitoxantrone can cause myocardial damage, including decreased left ventricular ejection fraction (LVEF) and congestive heart failure (CHF). Patients should be monitored for cardiac toxicity with baseline and periodic assessment of LVEF. Mitoxantrone can cause acute myeloid leukemia (AML), typically occurring 1-3 years after treatment.
Outcome:
Increased risk of cardiotoxicity
Mechanism:
Additive cardiotoxic effects
Outcome:
Altered anticoagulant effect
Mechanism:
May affect Vitamin-K dependent coagulation factors.
Outcome:
Reduced absorption of mitoxantrone
Mechanism:
Chelation
Most likely new formulation: Liposomal mitoxantrone for reduced cardiotoxicity. (Year 2026, 70% confidence).
Based on historical trends, mitoxantrone's use for multiple sclerosis is likely to decline due to cardiotoxicity concerns. A 5% increase in off-label oncology use is projected over the next five years.
Antineoplastic, Topoisomerase Inhibitor
Anthracenedione